Skip to main content
main-content

20.09.2017 | Original Article – Clinical Oncology | Ausgabe 1/2018

Journal of Cancer Research and Clinical Oncology 1/2018

Lung cancer screening with MRI: results of the first screening round

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 1/2018
Autoren:
Michael Meier-Schroers, Rami Homsi, Dirk Skowasch, Jens Buermann, Matthias Zipfel, Hans Heinz Schild, Daniel Thomas
Wichtige Hinweise
A comment to this article is available online at https://​doi.​org/​10.​1007/​s00432-018-2655-z.

Abstract

Purpose

To evaluate the suitability of MRI for lung cancer screening in a high-risk population.

Materials and methods

A 5-year lung cancer screening program comparing MRI and low-dose CT (LDCT) in a high-risk population was initiated. 224 subjects were examined with MRI and LDCT. Acquired MRI sequences were T2w MultiVane XD, balanced steady-state-free precession, 3D T1w GRE, and DWI with a maximum in-room-time of 20 min. Categorization and management of nodules were based on Lung-RADS. MRI findings were correlated with LDCT as a reference. Here, we report on the first screening round.

Results

MRI accurately detected 61 of 88 nodules 4–5 mm, 20 of 21 nodules 6–7 mm, 12 of 12 nodules 8–14 mm, 4 of 4 nodules ≥ 15 mm (solid nodules), and 8 of 11 subsolid nodules. Sensitivity/specificity of MRI for nodule detection was 69.3/96.4% for 4–5 mm, 95.2/99.6% for 6–7 mm, 100/99.6% for 8–14 mm, 100/100% for ≥ 15 mm (solid nodules), and 72.7/99.2% for subsolid nodules. The early recall rate was 13.8% for MRI and 12.5% for LDCT. Following Lung-RADS recommendations and based on interdisciplinary consensus, histology was obtained in eight subjects. The biopsy rate was 3.6% for MRI and 3.4% for LDCT. In all of these eight cases, the nodules were carcinomas, and all of them were accurately detected by MRI.

Conclusion

The results of the first screening round suggest that MRI is suitable for lung cancer screening with an excellent sensitivity and specificity for nodules ≥ 6 mm.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Journal of Cancer Research and Clinical Oncology 1/2018 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.